Alliance Global raised the firm’s price target on Journey Medical (DERM) to $16 from $10 and keeps a Buy rating on the shares post the Q3 report. The firm cites enthusiasm in the Emrosi launch for the target boost. It increased its peak revenue forecast to $250M from $200M for the drug.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
- Buy Rating for Journey Medical Corp Driven by Emrosi’s Market Success and Growth Potential
- Journey Medical Corporation Reports Strong Q3 2025 Growth
- Journey Medical reports Q3 EPS (9c), consensus (4c)
- Fourteen new option listings on November 12th
- Journey Medical Corporation (DERM) Q3 Earnings Cheat Sheet